NAT2 and tuberculosis: Also, it was proposed that INH dose adjustment based on the NAT2 genotype before prescribing TB treatment could improve clinical outcome and reduce the risk of INH-induced liver injury, however, the current level of evidence is not sufficient to recommend dose optimization (Azuma et al., 2013; McIlleron and Chirehwa, 2018; Khan and Das, 2022).